Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2022

Effet du guselkumab sur l'état de santé général chez les patients naïfs de produits biologiques atteints de rhumatisme psoriasique actif à la semaine 52 de l'essai de phase 3 DISCOVER-2, randomisé et contrôlé par placebo

Adv Ther. 2022 Oct;39(10):4632-4644 doi: 10.1007/s12325-022-02269-0

Yang F,

Hsia EC,

Han C,

Shiff NJ,

Shawi M,

Tillett W,

Mease PJ

In the latest study by Curtis, et al. guselkumab treatment regimens improved general HRQoL as measured by the EQ-5D-5L Index and EQ-VAS. In reaching this conclusion investigators aimed to determine the minimal important difference for both instruments and to understand the associations between patient-reported EQ-5D-5L Index and EQ-VAS scores as well as key PsA clinical features.

Keywords:

July 2022

Effet du bimekizumab sur les symptômes et l'impact de la maladie chez les patients atteints de rhumatisme psoriasique sur 3 ans : Résultats de l'étude BE ACTIVE

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353

Ink B,

Eells J,

Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.